

Plasma extracellular superoxide dismutase concentration, allelic variations in the SOD3 gene and risk of myocardial infarction and all-cause mortality in people with type 1 and type 2 diabetes

Kamel Mohammedi, Naïma Bellili-Muñoz, Stefan Marklund, Fathi Driss, Hervé Le Nagard, Thiago Patente, Frédéric Fumeron, Ronan Roussel, Samy Hadjadj, Michel Marre, et al.

► **To cite this version:**

Kamel Mohammedi, Naïma Bellili-Muñoz, Stefan Marklund, Fathi Driss, Hervé Le Nagard, et al.. Plasma extracellular superoxide dismutase concentration, allelic variations in the SOD3 gene and risk of myocardial infarction and all-cause mortality in people with type 1 and type 2 diabetes. Cardiovascular Diabetology, BioMed Central, 2015, 14 (1), pp.845. <10.1186/s12933-014-0163-2>. <inserm-01264487>

HAL Id: inserm-01264487

<http://www.hal.inserm.fr/inserm-01264487>

Submitted on 29 Jan 2016

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

ORIGINAL INVESTIGATION

Open Access

Plasma extracellular superoxide dismutase concentration, allelic variations in the *SOD3* gene and risk of myocardial infarction and all-cause mortality in people with type 1 and type 2 diabetes

Kamel Mohammedi^{1,2}, Naïma Bellili-Muñoz¹, Stefan L Marklund³, Fathi Driss^{4,5}, Hervé Le Nagard⁶, Thiago A Patente^{1,7}, Frédéric Fumeron^{1,8}, Ronan Roussel^{1,2,8}, Samy Hadjadj^{9,10,11,12}, Michel Marre^{1,2,8} and Gilberto Velho^{1*}

Abstract

Background: Oxidative stress is involved in development of diabetes complications. Extracellular superoxide dismutase (EC-SOD, SOD3) is a major extracellular antioxidant enzyme and is highly expressed in arterial walls. Advanced oxidation protein products (AOPP) and 8-iso-prostaglandin (isoprostane) are markers of oxidative stress. We investigated association of *SOD3* gene variants, plasma concentrations of EC-SOD, AOPP and isoprostane with myocardial infarction and mortality in diabetic patients.

Methods: We studied three cohorts designed to evaluate the vascular complications of diabetes: the GENEDIAB study (469 participants with type 1 diabetes at baseline; follow-up data for 259 participants), the GENESIS study (603 participants with type 1 diabetes at baseline; follow-up data for 525 participants) and the DIABHYCAR study (3137 participants with type 2 diabetes at baseline and follow-up). Duration of follow-up was 9, 5, and 5 years, respectively. Main outcome measures were incidence of myocardial infarction, and cardiovascular and total mortality during follow-up. Six single nucleotide polymorphisms in the *SOD3* locus were genotyped in the three cohorts. Plasma concentrations of EC-SOD, AOPP, and isoprostane were measured in baseline samples of GENEDIAB participants.

Results: In GENEDIAB/GENESIS pooled cohorts, the minor T-allele of rs2284659 variant was inversely associated with the prevalence at baseline (Odds Ratio 0.48, 95% CI 0.29–0.78, $p = 0.004$) and the incidence during follow-up of myocardial infarction (Hazard Ratio 0.58, 95% CI 0.40–0.83, $p = 0.003$) and with cardiovascular (HR 0.33, 95% CI 0.08–0.74, $p = 0.004$) and all-cause mortality (HR 0.44, 95% CI 0.21–0.73, $p = 0.0006$). The protective allele was associated with higher plasma EC-SOD and lower plasma AOPP concentrations in GENEDIAB. It was also inversely associated with incidence of myocardial infarction (HR 0.75, 95% CI 0.59–0.94, $p = 0.01$) and all-cause mortality (HR 0.87, 95% CI 0.79–0.97, $p = 0.008$) in DIABHYCAR.

Conclusions: The T-allele of rs2284659 in the promoter of *SOD3* was associated with a more favorable plasma redox status and with better cardiovascular outcomes in diabetic patients. Our results suggest that EC-SOD plays an important role in the mechanisms of vascular protection against diabetes-related oxidative stress.

Keywords: Oxidative Stress, SOD3, Myocardial Infarction, Mortality, Diabetes Mellitus

* Correspondence: gilberto.velho@inserm.fr

¹INSERM, UMR_S 1138, Centre de Recherche des Cordeliers, 15 rue de l'École de Médecine, 75006 Paris, France

Full list of author information is available at the end of the article

Introduction

Diabetes mellitus is associated with increased mortality rates [1,2]. Despite significant improvement of medical care during late decades, life expectancy of patients with type 1 or type 2 diabetes remains reduced as compared to age- and sex-matched nondiabetic subjects [1,2]. Cardiovascular disease is the leading cause of mortality and morbidity in patients with diabetes [1,2], and diabetic patients have a 3-fold higher risk than nondiabetic individuals of developing atherosclerosis and its clinical complications [1,3]. It is now well established that susceptibility to cardiovascular complications in diabetic patients are modulated by genetic factors [4].

Oxidative stress plays a major role in the development of microvascular and macrovascular complications of diabetes [5]. Superoxide dismutase (SOD) is a class of enzymes that catalyze the dismutation of superoxide into oxygen and hydrogen peroxide [6], and modulate the redox status of eukaryotic cells. The extracellular superoxide dismutase (EC-SOD or SOD3) is a major extracellular antioxidant enzyme, mainly located in the lymph, synovial fluid and plasma [7]. EC-SOD is highly expressed in blood vessels, particularly in arterial walls and represents up to 70% of the SOD activity in this tissue [7]. EC-SOD plays an important role in the protection against cardiovascular oxidative stress [8,9]. Advanced oxidation protein products (AOPP) and 8-iso-prostaglandin (isoprostane) were identified as markers of oxidative stress in patients with heart disease [10,11]. In the present study we investigated associations of allelic variation in the *SOD3* gene with the risk of myocardial infarction, cardiovascular death and all-cause mortality in two prospective cohorts of type 1 diabetic patients and one prospective cohort of type 2 diabetic patients. Correlations of genotypes, clinical outcomes, and circulating levels of EC-SOD, AOPP and isoprostane were also studied in type 1 diabetic participants.

Methods

Participants: GENEDIAB and GENESIS cohorts of type 1 diabetic patients

We studied two multicenter binational (Belgium and France) cohorts of type 1 diabetes patients designed to study the vascular complications of diabetes. The GENEDIAB (*Genétique de la Néphropathie DIABétique*) study was conducted in 494 people with type 1 diabetes and pre-proliferative or proliferative retinopathy [12]. GENESIS France-Belgium was a family-based study including 662 probands with type 1 diabetes and non-proliferative or proliferative retinopathy, and 578 first-degree relatives [13]. In the present investigation, we analyzed at baseline 469 GENEDIAB participants and 603 GENESIS probands for whom DNA samples were available. Clinical characteristics of GENEDIAB and GENESIS participants are shown in the Additional file 1: Table S1. In a

prospective observational study, subsets of GENEDIAB ($n = 261$) and GENESIS ($n = 549$) participants were followed until an end point was reached, or until February 2007. The subsets were composed of participants who attended outpatient clinics at least once during the follow-up period. In the present investigation, we analyzed follow-up data from 259 GENEDIAB participants and 525 GENESIS probands for whom DNA samples were available. Mean duration of follow-up was 9 ± 3 and 5 ± 2 years, respectively.

Participants: the DIABHYCAR cohort of type 2 diabetic patients

DIABHYCAR (*non-insulin-dependent DIABetes, HYper-tension, microalbuminuria or proteinuria, Cardiovascular events, and Ramipril*) was a multinational clinical trial conducted in patients with type 2 diabetes selected on the basis of persistent microalbuminuria (urinary albumin excretion, $UAE = 20-200$ mg/l) or macroalbuminuria ($UAE > 200$ mg/l) without renal failure (plasma creatinine < 150 μ mol/l) at baseline [14]. The trial tested whether a low dose of ramipril, an angiotensin converting enzyme (ACE) inhibitor, able to reduce UAE would also reduce cardiovascular and/or renal events such as myocardial infarction, stroke, acute heart failure, end-stage renal disease (ESRD), and cardiovascular death. The median duration of follow-up was 4.7 years. Results were negative regarding the drug effect and were published previously [14]. In the present work, we studied 3137 French participants of DIABHYCAR. Study protocols of the three cohorts were approved by the ethics committee of the University Hospital of Angers, France. All participants gave written informed consent.

Outcomes

Myocardial infarction was diagnosed as the occurrence of at least 2 out of 3 of the following criteria: constrictive chest pain lasting 20 minutes or longer, increased serum creatinine phosphokinase and/or troponine levels, or typical electrocardiographic changes. All-cause mortality was defined as death from any cause occurring during follow-up. Cardiovascular death was defined as sudden death, death following myocardial infarction, congestive heart failure and arrhythmias.

Clinical and laboratory procedures

Estimation of the glomerular filtration rate (eGFR) was computed with the Modification of Diet in Renal Disease (MDRD) formula. Plasma concentrations of EC-SOD, AOPP and isoprostane were measured in 440 GENEDIAB participants for whom fasting plasma-EDTA samples were available. Samples were collected at baseline and kept frozen at -80°C . EC-SOD was measured by ELISA as described previously [15]. Isoprostane was

measured by ELISA with a commercial kit (15-Isoprostane F2t ELISA Kit EA84, Oxford Biomedical Research). AOPP were measured by spectrophotometry using a microplate reader (MR 5000, Dynatech, Paris, France) [16]. Results were expressed as ng/ml (EC-SOD and isoprostane) and $\mu\text{mol/L}$ of chloramine-T equivalents (AOPP).

Five single nucleotide polymorphism (SNP) in the *SOD3* gene region (chromosome 4q21) were chosen in HapMap (public release #23) on the basis of giving information on ~90% of the allelic variation of SNPs with minor allele frequency $\geq 5\%$ at $r^2 > 0.8$ in haplotype blocks containing *SOD3*: rs2284659 (promoter, ~2.3 kb 5' from exon 1 start), rs2695234, rs17552548, rs758946 and rs2270224 (respectively ~1.8, ~2.3, ~4.8 and ~5.9 kb 3' from the end of exon 2/UTR). The rare missense functional variant rs1799895 (Arg213Gly, exon 2) was also genotyped [17]. Genotypes were determined by competitive allele-specific PCR genotyping system assays (KASP, LGC Genomics, Hoddeston, UK). Genotyping success rate was >92%. Genotyping was repeated in 5% of subjects with 100% concordance. Genotypes were in Hardy-Weinberg equilibrium (Pearson's chi-squared test with 1 degree of freedom $p > 0.05$) except for rs2695234 and rs2270224 in the DIABHYCAR cohort.

Statistical analysis

Results are expressed as mean \pm SEM except where stated otherwise. Differences between groups were assessed by analysis of variance (ANOVA), analysis of covariance (ANCOVA), and contingency table chi-square test. Genetic associations were assessed by regression models. Cox proportional hazards survival regression analyses were used to examine the effect of explanatory variables on time-related survival (or myocardial infarction-free) rates in prospective analyses. Logistic regression analyses were used for cross-sectional analyses. Hazard ratios (HR) or odds ratios (OR), respectively, with their 95% confidence intervals (CI) were computed for the minor alleles. The choice of a genetic model (dominant, codominant or recessive) for each of the analyses was based on the prevalence and/or incidence of the traits (myocardial infarction, all-cause mortality) by genotype. HR or OR were not computed for SNP with minor allele frequency (MAF) lower than 2% in the groups being compared, nor for genotypes not in Hardy-Weinberg equilibrium. Data were log-transformed for the analyses when the normality of the distribution was rejected by the Shapiro-Wilk *W* test. To increase statistical power, genetic analyses in type 1 diabetic participants were performed in GENEDIAB and GENESIS pooled studies with appropriate covariate adjustments to take into account cohort differences. Correction for multiple comparisons due to multiple SNP testing took into account the effective number of independent tests (Meff) based on the degree of linkage disequilibrium between SNPs [18]. Thus, $p \leq 0.01$ was

considered significant, unless stated otherwise. The power to detect allelic associations with the prevalence and the incidence of myocardial infarction, and with all-cause mortality in the GENEDIAB/GENESIS pooled study, was 90, 82 and 81%, respectively, for hazard ratio ≥ 1.5 and $\alpha = 0.01$. It was 99% for each outcome in DIABHYCAR cohort. Statistics were performed with the JMP software (SAS Institute Inc., Cary, NC).

Results

GENEDIAB and GENESIS cohorts: previous myocardial infarction at baseline by *SOD3* genotype

The prevalence of previous myocardial infarction at baseline in the pooled cohorts of patients with type 1 diabetes was 5.8% ($n = 62$). Genotype frequencies by history of previous myocardial infarction at baseline are shown in the Additional file 1: Table S2. The prevalence of myocardial infarction by rs2284659 genotype was 7.0% (GG), 5.4% (GT) and 2.2% (TT) suggesting a protective effect of the minor T-allele in a codominant model. A logistic regression analysis confirmed the inverse association of the T-allele with the prevalence of previous myocardial infarction (OR 0.48, 95% CI 0.29–0.78, $p = 0.004$, in a codominant model adjusted for sex, age, duration of diabetes, use of antihypertensive and lipid lowering medications, and for cohort membership).

GENEDIAB and GENESIS cohorts: clinical outcomes during follow-up

Characteristics of participants at baseline by the incidence of clinical outcomes during follow-up are shown in Table 1. Forty nine new cases of myocardial infarction occurred during follow-up. Its cumulative incidence was 6.3% (incidence rate 1.0 per 100 person-years). Individuals who had a myocardial infarction, compared to those who did not, were older, had a longer duration of diabetes, higher systolic blood pressure, lower eGFR, and were more likely to be of the male sex and to be taking antihypertensive and lipids lowering drugs. Previous myocardial infarction was more frequent at baseline in participants who developed new cases of myocardial infarction during the follow-up, as compared to those who did not. Death occurred in 72 participants during the follow-up. The cumulative incidence of total mortality was 9.2% (incidence rate 1.4 per 100 person-years). Causes of death included cardiovascular complications (38.9%), infectious diseases (15.3%), cancer (9.7%), acute metabolic complications (8.3%), kidney complications (2.8%) and other or undetermined etiologies (25.0%). Participants who died during follow-up, as compared to subjects who survived, were older, more frequently of the male sex, had a longer duration of diabetes, higher HbA1c, systolic and diastolic blood pressure, and UAE levels. They had lower eGFR and were more likely to

Table 1 GENEDIAB/GENESIS pooled study: Characteristics of participants at baseline by the incidence of myocardial infarction and all-cause mortality during follow-up

	Myocardial Infarction during follow-up			All-cause mortality		
	No	Yes	p	No	Yes	p
N	735	49		712	72	
Male sex (%)	53.8	69.4	0.03	53.7	70.8	0.005
Age (years)	42.6 ± 11.0	52.3 ± 12.5	<0.0001	42.7 ± 11.1	49.5 ± 12.6	<0.0001
Duration of diabetes (years)	27.1 ± 9.0	33.3 ± 11.6	0.0004	27.2 ± 9.1	31.3 ± 10.6	0.004
Body mass index (kg/m ²)	24.2 ± 3.5	24.9 ± 3.7	0.24	24.4 ± 3.5	23.6 ± 3.8	0.07
Systolic blood pressure (mmHg)	134 ± 19	144 ± 21	0.0007	134 ± 19	142 ± 18	0.0005
Diastolic blood pressure (mmHg)	77 ± 11	80 ± 11	0.07	76 ± 11	80 ± 10	0.004
HbA1c (%) and (mmol/mol)	8.5 ± 1.5 (70 ± 16)	8.9 ± 1.5 (74 ± 16)	0.08	8.5 ± 1.4 (69 ± 15)	9.4 ± 2.3 (79 ± 25)	<0.0001
Urinary albumin excretion (mg/l)	21 (177)	43 (836)	0.22	19 (157)	188 (900)	<0.0001
eGFR (ml/min)	86 ± 47	70 ± 31	0.02	86 ± 46	69 ± 56	<0.0001
Total cholesterol* (mmol/l)	5.67 ± 1.51	5.91 ± 1.07	0.28	5.65 ± 1.42	5.76 ± 1.67	0.97
Lipids lowering therapy (%)	7.9	16.3	0.04	8.3	11.1	0.41
Tobacco smoking (%)	42.0	47.9	0.42	41.2	59.2	0.004
Arterial hypertension (%)	60.8	83.7	0.001	60.5	84.7	<0.0001
Previous myocardial infarction (%)	3.8	22.9	<0.0001	3.9	21.1	<0.0001

Results expressed as mean ± SD, except urinary albumin excretion (UAE) expressed as median and interquartile range. Statistics of quantitative parameters are ANOVA performed with log-transformed data, or Wilcoxon test (UAE). eGFR: estimated glomerular filtration rate. *Data available only in the GENEDIAB cohort (n = 247). p < 0.05 is significant.

have a previous history of tobacco smoking, hypertension and myocardial infarction.

GENEDIAB and GENESIS cohorts: clinical outcomes during follow-up by *SOD3* genotypes

Genotype frequencies by the incidence of clinical outcomes during follow-up are shown in Table 2. The incidence of myocardial infarction by rs2284659 genotype was 7.6% (GG), 5.4% (GT) and 5.6% (TT), suggesting a protective effect of the minor T-allele in a dominant model. Cox proportional hazards survival regression analysis confirmed the inverse associations of rs2284659 T-allele with the incidence of myocardial infarction (HR 0.58, 95% CI 0.40–0.83, p = 0.003, in a dominant model, adjusted for sex, age, duration of diabetes, blood pressure, HbA1c, UAE, eGFR, use of antihypertensive and lipid lowering medications, tobacco smoking and cohort membership). The incidence of all-cause mortality by rs2284659 genotype was 8.9% (GG), 10.3% (GT) and 4.3% (TT), suggesting a protective effect of the minor T-allele in a recessive model. The association was confirmed by a Cox proportional hazards survival regression analysis (HR 0.44, 95% CI 0.21–0.73, p = 0.0006, for the T-allele in a recessive model adjusted for the same covariates as above). The T-allele protective effect remained significant when we considered only the cases of cardiovascular death (HR 0.33, 95% CI 0.08–0.74, p =

0.004). No other significant allelic association was observed with any of the outcomes.

GENEDIAB cohort: baseline correlations of EC-SOD and markers of oxidative stress

Plasma EC-SOD concentration at baseline was higher in women than in men (226 ± 18 vs 176 ± 11 ng/ml, p = 0.0004). It was positively correlated with systolic (R² = 0.04, p < 0.0001) and diastolic blood pressure (R² = 0.03, p < 0.0001), UAE (R² = 0.03, p = 0.001), total cholesterol (R² = 0.03, p = 0.0001), and inversely correlated with the body mass index (BMI; R² = 0.02, p = 0.004) and eGFR (R² = 0.12, p = 0.001). A stepwise regression analysis was performed to evaluate the independence of these correlations (Additional file 1: Table S3). Plasma EC-SOD concentration was entered in the model as the dependent variable. Age, duration of diabetes, HbA1c and the above mentioned variables were entered as independent covariates. Only eGFR, sex, systolic blood pressure, and BMI remained significantly correlated with EC-SOD and explained ~20% of the variance of the trait.

Plasma AOPP concentration at baseline was higher in women than in men (70 ± 3 vs 63 ± 2 μmol/l, p = 0.02), and was lower in subjects treated by ACE inhibitors (46 ± 3 vs 80 ± 2 μmol/l, p < 0.0001) or antihypertensive drugs (57 ± 36 vs 79 ± 29 μmol/l, p < 0.0001) than in subjects

Table 2 GENEDIAB/GENESIS pooled study: genotype frequency of *SOD3* variants by the incidence of myocardial infarction and all-cause mortality during follow-up

	Myocardial Infarction during follow-up				All-cause mortality			
	No	Yes	HR (95% C.I.)	p	No	Yes	HR (95% C.I.)	p
rs2284659								
GG	0.413 (268)	0.500 (22)	0.45 (0.25 – 0.77)	0.003	0.412 (265)	0.413 (26)	0.44 (0.21 – 0.73)	0.0006*
GT	0.456 (297)	0.386 (17)			0.448 (289)	0.524 (33)		
TT	0.131 (85)	0.114 (5)			0.140 (90)	0.063 (4)		
MAF	0.359	0.307			0.364	0.325		
rs1799895								
CC	0.983 (638)	1.000 (42)	-	**	0.983 (628)	1.000 (65)	-	**
CG	0.017 (11)	0 (0)			0.017 (11)	0.000 (0)		
GG	0	0 (0)			0	0 (0)		
MAF	0.008	0			0.009	0		
rs2695234								
GG	0.861 (566)	0.930 (40)	0.54 (0.09 – 1.70)	0.34	0.858 (558)	0.922 (59)	0.65 (0.32 – 1.08)	0.10
GA	0.130 (85)	0.047 (2)			0.133 (86)	0.062 (4)		
AA	0.009 (6)	0.023 (1)			0.009 (6)	0.016 (1)		
MAF	0.074	0.047			0.076	0.047		
rs17552548								
AA	0.894 (575)	0.975 (39)	-	**	0.904 (574)	0.857 (54)	1.47 (0.99 – 2.06)	0.06
GA	0.104 (67)	0.025 (1)			0.094 (60)	0.143 (9)		
GG	0.002 (1)	0 (0)			0.002 (1)	0 (0)		
MAF	0.054	0.013			0.049	0.071		
rs758946								
TT	0.857 (553)	0.930 (40)	0.49 (0.08 – 1.52)	0.25	0.853 (544)	0.936 (59)	0.68 (0.33 – 1.13)	0.15
TC	0.135 (87)	0.047 (2)			0.138 (88)	0.064 (4)		
CC	0.008 (5)	0.023 (1)			0.009 (6)	0 (0)		
MAF	0.075	0.047			0.078	0.032		
rs2270224								
GG	0.270 (169)	0.136 (6)	1.12 (0.65 – 1.91)	0.68	0.257 (158)	0.303 (20)	0.75 (0.50 – 1.04)	0.09*
GA	0.483 (304)	0.682 (30)			0.495 (306)	0.530 (35)		
AA	0.247 (155)	0.182 (8)			0.248 (153)	0.167 (11)		
MAF	0.489	0.523			0.496	0.432		

Genotype data expressed as frequency and (number of cases). SNPs are sorted in 5' to 3' order. Hazards ratio for the minor allele in a dominant or recessive* model, determined in Cox proportional hazards survival regressive model, adjusted for sex, age, duration of diabetes, blood pressure, HbA1c, UAE, eGFR, use of antihypertensive and lipid lowering medications, tobacco smoking and cohort membership. $p \leq 0.01$ is significant. MAF: minor allele frequency. **Statistics not computed due to low MAF (<0.02).

not receiving these medications. It was positively correlated with total cholesterol levels ($R^2 = 0.05$, $p < 0.0001$). Only the use of ACE inhibitors, and total cholesterol levels remained significantly correlated with AOPP concentration in a stepwise regression analysis and explained 38% and 6%, respectively, of its variance (data not shown). Plasma isoprostane concentration was higher in subjects treated by lipid lowering drugs than in those who were not (2.13 ± 0.20 vs 1.61 ± 0.05 ng/ml, $p = 0.005$). It was positively correlated with diastolic blood pressure ($R^2 = 0.02$, $p = 0.004$).

GENEDIAB cohort: EC-SOD and markers of oxidative stress at baseline by clinical outcomes during follow-up

Circulating levels of EC-SOD, AOPP and isoprostane at baseline by clinical outcomes during follow-up are shown in Table 3. Plasma EC-SOD concentration was not significantly associated with clinical outcomes during follow-up. Plasma AOPP concentration was higher in patients who died during the follow-up as compared to those who survived. Plasma isoprostane concentration was significantly higher in subjects who presented a clinical outcome (myocardial infarction or death

Table 3 GENEDIAB cohort: Plasma EC-SOD, AOPP and Isoprostane concentrations by clinical outcomes during follow-up

	N	EC-SOD (ng/ml)	N	AOPP (μmol/l)	N	Isoprostane (ng/ml)
Myocardial infarction						
Yes	25	194 ± 44	26	60 ± 6	26	2.37 ± 0.24
No	208	196 ± 15	214	66 ± 2	226	1.52 ± 0.08
p		0.51		0.49		0.0003
All-cause mortality						
Yes	47	195 ± 30	40	73 ± 6	42	2.22 ± 0.20
No	194	192 ± 14	209	56 ± 4	221	1.71 ± 0.12
p		0.57		0.004		0.002

Results expressed as mean ± SEM. Statistics are ANCOVA adjusted for sex, age, BMI, systolic blood pressure and eGFR (EC-SOD), for sex, age, total cholesterol concentration, and use of ACE inhibitors (AOPP), and for sex, age, diastolic blood pressure, and use of lipid lowering drugs (isoprostane). p < 0.05 is significant.

from any cause) during follow-up as compared to those who did not.

GENEDIAB cohort: EC-SOD and markers of oxidative stress at baseline by SOD3 genotypes

Genotype-related effects on EC-SOD, AOPP and isoprostane are shown in Table 4. Carriers of the protective T-allele of rs2284659 had significantly higher plasma EC-SOD concentration than homozygous GG carriers. Moreover, carriers of the TT genotype had significantly lower plasma AOPP concentration than G-allele carriers. Heterozygous carriers of the rare G-allele of the missense (Arg213Gly) functional variant rs1799895 had a ~6-fold increase in plasma EC-SOD concentration. Higher plasma AOPP concentration was also observed for GG carriers of rs2270224 and G-allele carriers of rs17552548 (p < 0.0001; data not shown). We observed no genotype-related association with plasma isoprostane concentration.

Table 4 GENEDIAB cohort: Plasma EC-SOD, AOPP and Isoprostane concentrations at baseline by SOD3 genotypes

	EC-SOD (ng/ml)	AOPP (μmol/l)	Isoprostane (ng/ml)
rs2284659			
GG (n)	165 ± 17 (165)	66 ± 3 (156)	1.98 ± 0.11 (162)
GT (n)	230 ± 16 (172)	64 ± 3 (171)	1.92 ± 0.11 (181)
TT (n)	222 ± 25 (74)	55 ± 4 (73)	1.98 ± 0.16 (73)
p	0.007	0.02	0.90
rs1799895			
CC (n)	169 ± 6 (400)	64 ± 2 (390)	1.93 ± 0.10 (407)
CG (n)	1156 ± 32 (12)	52 ± 10 (12)	1.78 ± 0.34 (12)
p	<0.0001	0.34	0.41

Results expressed as mean ± SEM. Statistics are ANCOVA adjusted for sex, age, BMI, systolic blood pressure and eGFR (EC-SOD), for sex, age, total cholesterol concentration, and use of ACE inhibitors (AOPP), and for sex, age, diastolic blood pressure, and use of lipid lowering drugs (isoprostane). p ≤ 0.01 is significant.

DIABHYCAR study: clinical outcomes during follow-up by SOD3 genotype

Myocardial infarction was diagnosed in 95 participants and death occurred in 456 participants during the follow-up of the DIABHYCAR type 2 diabetes study. The cumulative incidence of myocardial infarction and total mortality was 3.0% and 14.5%, respectively, and their incidence rate was 0.7 and 3.3 per 100 person-years. Causes of death included cardiovascular complications and sudden death (40.0%), infectious diseases (2.4%), cancer (26.5%), acute metabolic complications (0.2%), end stage renal disease (ESRD, 0.9%) and other or undetermined etiologies (30.0%). Characteristics of participants at baseline by the incidence of myocardial infarction and all-cause mortality during the follow-up are shown in Table 5. Patients who died during follow-up, as compared to those who survived, were older, more frequently of the male sex, had a longer duration of diabetes, higher systolic blood pressure and UAE levels. They had lower BMI and eGFR levels, and were more likely to be taking antiplatelet drugs, and to have a previous history of hypertension and myocardial infarction. Genotype frequencies by the incidence of clinical outcomes during follow-up are shown in Additional file 1: Table S4. The incidence of outcomes by rs2284659 genotype was 3.6% (GG), 2.6% (GT) and 2.3% (TT) for myocardial infarction, and 16.3% (GG), 13.4% (GT) and 14.1% (TT) for all-cause mortality, suggesting a protective effect of the minor T-allele in a dominant model. Cox proportional hazards survival regression analyses confirmed the inverse associations of rs2284659 T-allele with the incidence of myocardial infarction (HR 0.75, 95% CI 0.59–0.94, p = 0.01) and all-cause mortality (HR 0.87, 95% CI 0.79–0.97, p = 0.008) in a dominant model, adjusted for sex, age, duration of diabetes, BMI, blood pressure, UAE, eGFR, hypertension and antiplatelet drugs and study treatment. A nominal inverse association was also observed when we considered only cardiovascular causes of death (HR 0.83, 95% CI 0.69–0.99,

Table 5 DIABHYCAR cohort: Characteristics of participants at baseline by the incidence of myocardial infarction and all-cause mortality during follow-up

	Myocardial infarction during follow-up			All-cause mortality		
	No	Yes	p	No	Yes	p
N	3042	95		2554	438	
Male sex (%)	73.0	75.8	0.54	72.2	77.2	0.03
Age (years)	65.6 ± 8.3	65.9 ± 8.8	0.79	64.8 ± 8.1	70.5 ± 8.5	<0.0001
Duration of diabetes (years)	10.4 ± 7.7	11.3 ± 8.6	0.49	10.1 ± 7.6	12.3 ± 8.2	<0.0001
Body mass index (kg/m ²)	29.4 ± 4.6	29.1 ± 4.2	0.60	29.5 ± 4.6	28.8 ± 4.9	0.0008
Systolic blood pressure (mmHg)	144 ± 13	146 ± 16	0.14	144 ± 13	146 ± 13	0.007
Diastolic blood pressure (mmHg)	82 ± 8	81 ± 8	0.29	82 ± 8	82 ± 8	0.99
HbA1c (%) and (mmol/mol)	7.9 ± 1.8 (62 ± 19)	8.2 ± 1.8 (66 ± 20)	0.06	7.8 ± 1.7 (62 ± 19)	8.0 ± 2.0 (64 ± 22)	0.35
Urinary albumin excretion (mg/l)	76 (144)	78 (162)	0.92	72 (130)	109 (278)	<0.0001
eGFR (ml/min)	78 ± 22	75 ± 20	0.14	78 ± 22	72 ± 21	<0.0001
Total cholesterol (mmol/l)	5.79 ± 1.07	6.00 ± 1.25	0.18	5.78 ± 1.05	5.84 ± 1.15	0.37
HDL- cholesterol (mmol/l)	1.32 ± 0.36	1.25 ± 0.26	0.15	1.32 ± 0.35	1.29 ± 0.34	0.17
LDL- cholesterol (mmol/l)	3.52 ± 0.88	3.72 ± 1.02	0.10	3.53 ± 0.87	3.51 ± 0.92	0.61
Triglycerides (mmol/l)	1.83 (1.36)	1.81 (1.77)	0.53	1.84 (1.32)	1.84 (1.49)	0.69
Lipids lowering therapy (%)	35.5	33.7	0.71	36.0	32.2	0.12
Antiplatelet drugs (%)	18.8	16.8	0.63	17.0	28.5	<0.0001
Tobacco smoking (%)	14.4	13.7	0.84	14.2	14.6	0.83
Arterial hypertension (%)	56.1	60.0	0.44	54.9	64.4	0.0002
Previous myocardial infarction (%)	5.3	10.5	0.03	4.9	8.5	0.003

Results expressed as mean ± SD, except urinary albumin excretion (UAE) and triglycerides expressed as median and interquartile range. Statistics of quantitative parameters are ANOVA performed with log-transformed data, or Wilcoxon test (UAE, triglycerides). eGFR: estimated glomerular filtration rate. p < 0.05 is significant.

p = 0.03, for the T-allele in a dominant model, same adjustments as above).

Discussion

In the present investigation, we observed associations of a variant in the promoter region of the *SOD3* gene with cardiovascular morbidity and mortality in prospective cohorts of type 1 and type 2 diabetic patients. The minor T-allele of rs2284659 was inversely associated with the prevalence of myocardial infarction at baseline and with the incidence during follow-up of myocardial infarction, cardiovascular death and all-cause mortality in subjects with type 1 diabetes from GENESIS and GENEDIAB studies. The same allele was also inversely associated with the incidence of myocardial infarction and all-cause mortality during follow-up in the DIABHYCAR cohort of type 2 diabetic subjects. The protective T-allele of rs2284659 was associated with higher plasma EC-SOD and lower plasma AOPP concentrations in GENEDIAB.

AOPP concentration reflects the oxidation of plasma proteins, especially albumin, and is a reliable marker of oxidant-mediated protein damage [16]. Isoprostanes are a biologically active product of arachidonic acid metabolism formed as the result of oxygenation of polyunsaturated fatty acids. Circulating isoprostane concentration

reflects lipid peroxidation associated with oxidative stress [11]. We observed higher plasma AOPP and isoprostane concentrations at baseline in type 1 diabetic subjects who died during the follow-up than in subjects who were alive at the end of the study. Isoprostane concentration at baseline was also higher in incident case of myocardial infarction. Previous studies have shown plasma AOPP and isoprostane to be an independent risk factors for coronary artery disease [10,11,19,20].

SOD3 gene and risk of cardiovascular morbidity and mortality

Data from the literature on the association of the genes encoding the SOD enzymes with cardiovascular complications are scarce. We have previously observed in the DIABHYCAR cohort associations of *SOD1* variants with cardiovascular mortality [21]. Mollsten and coworkers observed an association of a missense variant of *SOD2* with increased cardiovascular risk in a Danish cohort of type 1 diabetic patients [22]. Regarding *SOD3*, investigations dealt mostly with the rare functional variant rs1799895 (Arg213Gly) in the heparin-binding domain of EC-SOD. The Gly allele is associated with decreased EC-SOD affinity for heparin, decreased tissue binding, and a 6-to-10-fold increase in circulating EC-SOD

concentration [17,23,24]. Despite higher circulating levels of the enzyme, the 213Gly isoform was shown to present only minimal anti-oxidant effects in the vascular wall [24], the loss of function being attributed to decreased tissue binding. Associations of the Gly allele with cardiovascular risk factors, morbidity or mortality were reported in a few studies [25,26].

Genetic analysis of rs1799895 in our study was inconclusive due to the very low frequency of the Gly allele in our cohorts. It is therefore unlikely that the associations we have observed with the promoter rs2284659 could be explained by a rs1799895 Gly allele effect. Moreover, linkage disequilibrium between the two variants was not strong ($D' = 0.687$ and $r^2 = 0.009$). The genetic mechanism behind the allelic associations that we have observed remains unclear, as rs2284659 does not seem to modify known transcription factor binding sites. However, it is noteworthy that rs2284659 is in complete linkage disequilibrium with two other SNPs in the promoter of *SOD3* (rs2159757 and rs13435617) that might affect transcription. The region surrounding and including rs2159757 matches the binding site for the PBX (pre-B-cell leukemia) family of transcription factors, and that surrounding and including rs13435617 matches the binding sites for HLF (hepatic leukemia factor) and E4BP4 (adenovirus E4 promoter-binding protein) transcription factors (<http://consite.genereg.net>). Interestingly, PBX transcription factors play a significant role in the morphogenesis, patterning and formation of the ventricular outflow tract (OFT). Mice lacking *PBX1* gene have a range of OFT malformations, including failure of cardiac septation [27]. A missense variant of *PBX3* (p. A136V) predicted to be deleterious for transcriptional function was four times more frequent in patients with congenital heart defects as compared to controls [28]. E4BP4 is implicated in the regulation of mammalian circadian oscillatory mechanism, anti-inflammatory response and cell survival. E4BP4 is expressed in the human heart and was shown to inhibit apoptotic proteins and to be overexpressed in cardiomyocytes following myocardial infarction [29]. The implication of these transcription factors on *SOD3* expression needs to be evaluated.

Oxidative stress and vascular complications of diabetes

Oxidative stress is involved in the pathogenesis of atherosclerosis [30]. Increased production of reactive oxygen species (ROS) impairs endothelial function and endothelium-dependent vasodilation in humans, notably by inactivation of NO [31,32]. Oxidative stress also induces cell proliferation, hypertrophy, cardiac remodeling, apoptosis and inflammation in endothelial and smooth cells of the vascular wall and in myocardial cells [31,33,34]. Moreover, oxidative stress is associated with the metabolic syndrome and with many risk factors for atherosclerosis such as hypertension,

dyslipidemia, obesity and diabetes [35]. Biomarkers of oxidative stress predict the risk of mortality in patients with heart disease [36]. Oxidative stress was shown to play a role in the premature vascular morbidity and mortality in people with diabetes [37]. Studies in animal models corroborate the implication of oxidative stress in cardiovascular morbidity and mortality related to diabetes [38,39].

Antioxidant enzymes such as the SODs scavenge ROS and inhibit NO degradation in the vascular wall [33]. The vascular wall contains large amounts of EC-SOD, which is produced and secreted to the extracellular space by smooth muscle cells [7,40]. The expression of *SOD3* was shown to be significantly reduced, and endothelium-bound EC-SOD activity to be correlated to flow-dependent endothelium-mediated dilation in subjects with coronary artery disease, suggesting that reduced EC-SOD activity might contribute to endothelial dysfunction in these patients [8]. Overexpression of *SOD3* in human vascular endothelial cells *in vitro* was shown to decrease endothelial-cell-derived superoxide production and LDL oxidation [9]. The implication of EC-SOD in cardiovascular protection is supported by studies in animal models. The overexpression of *SOD3* in transgenic mice was associated with protection of myocardial function after global ischemia/reperfusion [41]. Increased EC-SOD levels by adenovirus-mediated transfection of human *SOD3* cDNA was associated with protection against myocardial stunning and with decreased reperfusion infarct size in a rabbit model of ischemia/reperfusion injury [42]. Atherosclerosis was not increased in *SOD3* knockout mice given an atherogenic diet [43]. However, in an experimental model of focal cerebral ischemia, total infarct volume was 81% greater and hemiparesis more severe in *SOD3* knockout mice as compared to wild-type animals [44], while mice overexpressing *SOD3* had increased resistance to ischemia [45].

Strengths and limitations

The main strengths of our study are the assessment of clinical phenotypes (myocardial infarction, cardiovascular and all-cause mortality) in three prospective cohorts of type 1 and type 2 diabetes and the genotyping of tagSNPs covering the haplotype block containing *SOD3*. We also investigated associations of the clinical phenotypes and *SOD3* genotypes with three markers of redox status. Overproduction of ROS and oxidative stress induced by chronic hyperglycemia are features of type 1 and type 2 diabetes [5]. Nevertheless, despite the observation in our study of similar genetic associations in both types of diabetes, we acknowledge that proper replication studies are needed in type 1 and type 2 diabetes cohorts. Our study has limitations, notably in issues related to the measurement of the redox biomarkers. AOPP and isoprostane were assayed in plasma-EDTA

samples collected at baseline and kept frozen for ~20 years, and only in a subset of participants. These issues might have affected, at least in part, comparisons of plasma AOPP and isoprostane concentrations between groups. Moreover, measurements of redox biomarkers were performed only in GENEDIAB participants for whom plasma samples were available, and thus were not replicated in the present investigation. Another limitation of the study is the relatively small sample size of our type 1 diabetes cohorts and the small number of new cases of myocardial infarction during follow-up. The statistical power was adequate to detect SNP effects with HR ≥ 1.5 , but might have been insufficient to detect effects of smaller magnitude.

Conclusions

We have observed associations of rs2284659 in the promoter of the *SOD3* gene with myocardial infarction and with cardiovascular and all-cause mortality in subjects with type 1 or type 2 diabetes. The protective allele was associated with increased EC-SOD and decreased AOPP plasma concentrations, and thus with a more favorable plasma redox status. Our results suggest that EC-SOD plays a role in the mechanisms of vascular protection against oxidative stress in diabetic patients. Further studies are required to identify the functional variants and the molecular mechanisms beyond these allelic associations.

Additional file

Additional file 1: Supplemental Tables.

Abbreviations

ACE: Angiotensin converting enzyme; ANCOVA: Analysis of covariance; ANOVA: Analysis of variance; AOPP: Advanced oxidation protein products; BMI: Body mass index; CI: Confidence intervals; eGFR: Estimated glomerular filtration rate; EC-SOD: Extracellular superoxide dismutase; HR: Hazard ratio; MAF: Minor allele frequency; MDRD: "Modification of Diet in Renal Disease" formula; OR: Odds ratio; ROS: Reactive oxygen species; SNP: Single nucleotide polymorphism; SOD: Superoxide dismutase; UAE: Urinary albumin excretion.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

KM and GV contributed to conception and design of the study, researched data (acquisition, analysis, interpretation) and drafted the manuscript. FF, RR, SH and MM contributed to conception and design of the study, and reviewed/edited the manuscript. NB-M, SLM, FD, HLN and TAP researched data (acquisition, analysis, interpretation) and reviewed/edited the manuscript. All authors approved the current version of the manuscript.

Acknowledgements

The authors acknowledge the expert help of François Cohen (IAME, INSERM UMR 1137, Paris, France) in analyzing isoprostane measurements. This work was supported by grants from Association Diabète Risque Vasculaire (ADRV), and Association L'Aide Aux Jeunes Diabétiques (AJD), France. TAP was supported by a grant from the FAPESP (Sao Paulo Research Foundation), Brazil. The analysis and interpretation of the data has been done without the participation of these organizations.

Author details

¹INSERM, UMR_S 1138, Centre de Recherche des Cordeliers, 15 rue de l'École de Médecine, 75006 Paris, France. ²Assistance Publique Hôpitaux de Paris, DHU FIRE, Department of Diabetology, Endocrinology and Nutrition, Bichat Hospital, 46 rue Henri Huchard, 75018 Paris, France. ³Department of Medical Biosciences, Umeå University, Building 6M, 90185 Umeå, Sweden. ⁴INSERM, Research Unit 773, 16 rue Henri Huchard, 75018 Paris, France. ⁵Assistance Publique Hôpitaux de Paris, Department of Biochemistry, Bichat Hospital, 46 rue Henri Huchard, 75018 Paris, France. ⁶INSERM, Research Unit 1137 - IAME, 16 rue Henri Huchard, 75018 Paris, France. ⁷Laboratório de Endocrinologia Celular e Molecular (LIM-25), Faculdade de Medicina da Universidade de São Paulo (FMUSP), Avenida Dr. Arnaldo 455, CEP 01246903 São Paulo, SP, Brazil. ⁸Sorbonne Paris Cité, UFR de Médecine, Université Paris Diderot, 16 rue Henri Huchard, 75018 Paris, France. ⁹Department of Endocrinology and Diabetology, Centre Hospitalier Universitaire de Poitiers, 2 Rue de la Milétrie, 86021 Poitiers, France. ¹⁰INSERM, Research Unit 1082, 2 Rue de la Milétrie, 86021 Poitiers, France. ¹¹INSERM, CIC 1402, 2 Rue de la Milétrie, 86021 Poitiers, France. ¹²UFR de Médecine et Pharmacie, Université de Poitiers, 6 Rue de la Milétrie, 86073 Poitiers, France.

Received: 11 September 2014 Accepted: 10 December 2014

Published online: 15 January 2015

References

- Soedamah-Muthu SS, Fuller JH, Mulnier HE, Raleigh VS, Lawrenson RA, Colhoun HM: All-cause mortality rates in patients with type 1 diabetes mellitus compared with a non-diabetic population from the UK general practice research database, 1992–1999. *Diabetologia* 2006, **49**(4):660–666.
- Seshasai SR, Kaptoge S, Thompson A, Di Angelantonio E, Gao P, Sarwar N, Whincup PH, Mukamal KJ, Gillum RF, Holme I, Njolstad I, Fletcher A, Nilsson P, Lewington S, Collins R, Gudnason V, Thompson SG, Sattar N, Selvin E, Hu FB, Danesh J: Diabetes mellitus, fasting glucose, and risk of cause-specific death. *N Engl J Med* 2011, **364**(9):829–841.
- Almdal T, Scharling H, Jensen JS, Vestergaard H: The independent effect of type 2 diabetes mellitus on ischemic heart disease, stroke, and death: a population-based study of 13,000 men and women with 20 years of follow-up. *Arch Intern Med* 2004, **164**(13):1422–1426.
- Pfister R, Barnes D, Luben RN, Khaw KT, Wareham NJ, Langenberg C: Individual and cumulative effect of type 2 diabetes genetic susceptibility variants on risk of coronary heart disease. *Diabetologia* 2011, **54**(9):2283–2287.
- Giacco F, Brownlee M: Oxidative stress and diabetic complications. *Circ Res* 2010, **107**(9):1058–1070.
- Fridovich I: Superoxide radical and superoxide dismutases. *Annu Rev Biochem* 1995, **64**:97–112.
- Stralin P, Karlsson K, Johansson BO, Marklund SL: The interstitium of the human arterial wall contains very large amounts of extracellular superoxide dismutase. *Arterioscler Thromb Vasc Biol* 1995, **15**(11):2032–2036.
- Landmesser U, Merten R, Spiekermann S, Buttner K, Drexler H, Hornig B: Vascular extracellular superoxide dismutase activity in patients with coronary artery disease: relation to endothelium-dependent vasodilation. *Circulation* 2000, **101**(19):2264–2270.
- Takatsu H, Tasaki H, Kim HN, Ueda S, Tsutsui M, Yamashita K, Toyokawa T, Morimoto Y, Nakashima Y, Adachi T: Overexpression of EC-SOD suppresses endothelial-cell-mediated LDL oxidation. *Biochem Biophys Res Commun* 2001, **285**(1):84–91.
- Kaneda H, Taguchi J, Ogasawara K, Aizawa T, Ohno M: Increased level of advanced oxidation protein products in patients with coronary artery disease. *Atherosclerosis* 2002, **162**(1):221–225.
- Leleiko RM, Vaccari CS, Sola S, Merchant N, Nagamia SH, Thoenes M, Khan BV: Usefulness of elevations in serum choline and free F2-isoprostane to predict 30-day cardiovascular outcomes in patients with acute coronary syndrome. *Am J Cardiol* 2009, **104**(5):638–643.
- Marre M, Jeunemaitre X, Gallois Y, Rodier M, Chatellier G, Sert C, Dusselier L, Kahal Z, Chaillous L, Halimi S, Muller A, Sackmann H, Bauduceau B, Bled F, Passa P, Alhenc-Gelas F: Contribution of genetic polymorphism in the renin-angiotensin system to the development of renal complications in insulin-dependent diabetes: Genetique de la Nephropathie Diabetique (GENEDIAB) study group. *J Clin Invest* 1997, **99**(7):1585–1595.
- Hadjadj S, Pean F, Gallois Y, Passa P, Aubert R, Weekers L, Rigalleau V, Bauduceau B, Bekhraz A, Roussel R, Dussol B, Rodier M, Marechaud R, Lefebvre PJ, Marre M: Different patterns of insulin resistance in relatives

- of type 1 diabetic patients with retinopathy or nephropathy: the Genesis France-Belgium Study. *Diabetes Care* 2004, **27**(11):2661–2668.
14. Marre M, Lievre M, Chatellier G, Mann JF, Passa P, Menard J: **Effects of low dose ramipril on cardiovascular and renal outcomes in patients with type 2 diabetes and raised excretion of urinary albumin: randomised, double blind, placebo controlled trial (the DIABHYCAR study).** *BMJ* 2004, **328**(7438):495.
 15. Karlsson K, Marklund SL: **Plasma clearance of human extracellular-superoxide dismutase C in rabbits.** *J Clin Invest* 1988, **82**(3):762–766.
 16. Witko-Sarsat V, Friedlander M, Capeillere-Blandin C, Nguyen-Khoa T, Nguyen AT, Zingraff J, Jungers P, Descamps-Latscha B: **Advanced oxidation protein products as a novel marker of oxidative stress in uremia.** *Kidney Int* 1996, **49**(5):1304–1313.
 17. Sandstrom J, Nilsson P, Karlsson K, Marklund SL: **10-fold increase in human plasma extracellular superoxide dismutase content caused by a mutation in heparin-binding domain.** *J Biol Chem* 1994, **269**(29):19163–19166.
 18. Nyholt DR: **A simple correction for multiple testing for single-nucleotide polymorphisms in linkage disequilibrium with each other.** *Am J Hum Genet* 2004, **74**(4):765–769.
 19. Descamps-Latscha B, Witko-Sarsat V, Nguyen-Khoa T, Nguyen AT, Gausson V, Mothu N, London GM, Jungers P: **Advanced oxidation protein products as risk factors for atherosclerotic cardiovascular events in nondiabetic predialysis patients.** *Am J Kidney Dis* 2005, **45**(1):39–47.
 20. Feng Y, Shen C, Ma G, Wang J, Chen Z, Dai Q, Zhi H, Yang C, Fu Q, Shang G, Guan Y: **Prolonged pain to hospital time is associated with increased plasma advanced oxidation protein products and poor prognosis in patients with percutaneous coronary intervention for ST-elevation myocardial infarction.** *Heart Vessels* 2010, **25**(5):374–378.
 21. Neves AL, Mohammedi K, Emery N, Roussel R, Fumeron F, Marre M, Velho G: **Allelic variations in superoxide dismutase-1 (SOD1) gene and renal and cardiovascular morbidity and mortality in type 2 diabetic subjects.** *Mol Genet Metab* 2012, **106**:359–365.
 22. Mollsten A, Jorsal A, Lajer M, Vionnet N, Tarnow L: **The V16A polymorphism in SOD2 is associated with increased risk of diabetic nephropathy and cardiovascular disease in type 1 diabetes.** *Diabetologia* 2009, **52**:2590–2593.
 23. Adachi T, Yamada H, Yamada Y, Morihara N, Yamazaki N, Murakami T, Futenma A, Kato K, Hirano K: **Substitution of glycine for arginine-213 in extracellular-superoxide dismutase impairs affinity for heparin and endothelial cell surface.** *Biochem J* 1996, **313**(Pt 1):235–239.
 24. Chu Y, Alwahdani A, Iida S, Lund DD, Faraci FM, Heistad DD: **Vascular effects of the human extracellular superoxide dismutase R213G variant.** *Circulation* 2005, **112**(7):1047–1053.
 25. Marklund SL, Nilsson P, Israelsson K, Schampi I, Peltonen M, Asplund K: **Two variants of extracellular-superoxide dismutase: relationship to cardiovascular risk factors in an unselected middle-aged population.** *J Intern Med* 1997, **242**(1):5–14.
 26. Juul K, Tybjaerg-Hansen A, Marklund S, Heegaard NH, Steffensen S, Sillisen H, Jensen G, Nordestgaard BG: **Genetically reduced antioxidative protection and increased ischemic heart disease risk: the Copenhagen City heart study.** *Circulation* 2004, **109**(1):59–65.
 27. Chang CP, Stankunas K, Shang C, Kao SC, Twu KY, Cleary ML: **Pbx1 functions in distinct regulatory networks to pattern the great arteries and cardiac outflow tract.** *Development* 2008, **135**(21):3577–3586.
 28. Arrington CB, Dowse BR, Bleyl SB, Bowles NE: **Non-synonymous variants in pre-B cell leukemia homeobox (PBX) genes are associated with congenital heart defects.** *Eur J Med Genet* 2012, **55**(4):235–237.
 29. Weng YJ, Hsieh DJ, Kuo WW, Lai TY, Hsu HH, Tsai CH, Tsai FJ, Lin DY, Lin JA, Huang CY, Tung KC: **E4BP4 is a cardiac survival factor and essential for embryonic heart development.** *Mol Cell Biochem* 2010, **340**(1-2):187–194.
 30. Libby P, Ridker PM, Hansson GK: **Progress and challenges in translating the biology of atherosclerosis.** *Nature* 2011, **473**(7347):317–325.
 31. Higashi Y, Noma K, Yoshizumi M, Kihara Y: **Endothelial function and oxidative stress in cardiovascular diseases.** *Circ J* 2009, **73**(3):411–418.
 32. Patel H, Chen J, Das KC, Kavdia M: **Hyperglycemia induces differential change in oxidative stress at gene expression and functional levels in HUVEC and HMVEC.** *Cardiovasc Diabetol* 2013, **12**:142.
 33. Faraci FM, Didion SP: **Vascular protection: superoxide dismutase isoforms in the vessel wall.** *Arterioscler Thromb Vasc Biol* 2004, **24**(8):1367–1373.
 34. Rosa CM, Xavier NP, Henrique Campos D, Fernandes AA, Cezar MD, Martinez PF, Cicogna AC, Gimenes C, Gimenes R, Okoshi MP, Okoshi K: **Diabetes mellitus activates fetal gene program and intensifies cardiac remodeling and oxidative stress in aged spontaneously hypertensive rats.** *Cardiovasc Diabetol* 2013, **12**(1):152.
 35. Hopps E, Noto D, Caimi G, Averna MR: **A novel component of the metabolic syndrome: the oxidative stress.** *Nutr Metab Cardiovasc Dis* 2010, **20**(1):72–77.
 36. Heslop CL, Frohlich JJ, Hill JS: **Myeloperoxidase and C-reactive protein have combined utility for long-term prediction of cardiovascular mortality after coronary angiography.** *J Am Coll Cardiol* 2010, **55**(11):1102–1109.
 37. Doney AS, Lee S, Leese GP, Morris AD, Palmer CN: **Increased cardiovascular morbidity and mortality in type 2 diabetes is associated with the glutathione S transferase theta-null genotype: a Go-DARTS study.** *Circulation* 2005, **111**(22):2927–2934.
 38. Stull LB, Leppo MK, Szweida L, Gao WD, Marban E: **Chronic treatment with allopurinol boosts survival and cardiac contractility in murine postischemic cardiomyopathy.** *Circ Res* 2004, **95**(10):1005–1011.
 39. Zhang S, Liu H, Amarsingh GV, Cheung CC, Hogg S, Narayanan U, Zhang L, McHarg S, Xu J, Gong D, Kennedy J, Barry B, Choong YS, Phillips AR, Cooper GJ: **Diabetic cardiomyopathy is associated with defective myocellular copper regulation and both defects are rectified by divalent copper chelation.** *Cardiovasc Diabetol* 2014, **13**:100.
 40. Oury TD, Day BJ, Crapo JD: **Extracellular superoxide dismutase in vessels and airways of humans and baboons.** *Free Radic Biol Med* 1996, **20**(7):957–965.
 41. Chen EP, Bittner HB, Davis RD, Folz RJ, Van Trigt P: **Extracellular superoxide dismutase transgene overexpression preserves postischemic myocardial function in isolated murine hearts.** *Circulation* 1996, **94**(9 Suppl):II412–417.
 42. Li Q, Bolli R, Qiu Y, Tang XL, Guo Y, French BA: **Gene therapy with extracellular superoxide dismutase protects conscious rabbits against myocardial infarction.** *Circulation* 2001, **103**(14):1893–1898.
 43. Sentman ML, Brannstrom T, Westerlund S, Laukkanen MO, Yla-Herttuala S, Basu S, Marklund SL: **Extracellular superoxide dismutase deficiency and atherosclerosis in mice.** *Arterioscler Thromb Vasc Biol* 2001, **21**(9):1477–1482.
 44. Sheng H, Brady TC, Pearlstein RD, Crapo JD, Warner DS: **Extracellular superoxide dismutase deficiency worsens outcome from focal cerebral ischemia in the mouse.** *Neurosci Lett* 1999, **267**(1):13–16.
 45. Sheng H, Bart RD, Oury TD, Pearlstein RD, Crapo JD, Warner DS: **Mice overexpressing extracellular superoxide dismutase have increased resistance to focal cerebral ischemia.** *Neuroscience* 1999, **88**(1):185–191.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

